Cardiology pp 283-287 | Cite as

Inhibition of the Renin Angiotensin System in the Treatment of Hypertension

  • R. Fagard
  • P. Lijnen
  • J. Staessen
  • A. Amery


Renin is a proteolytic enzyme that is synthetized, stored and secreted mainly by the juxtaglomerular apparatus of the kidney. The release of renin is regulated a.o. by renal baroreceptors, by sodium-sensitive mechanisms at the level of the macula densa, by the sympathetic nervous system, prostaglandins and angiotensin II. Renin acts on its substrate, angiotensinogen, an alpha-2-globulin produced in the liver and present in the plasma to form the decapeptide angiotensin I, which is practically devoid of pressor activity. The converting-enzyme, a peptidyl-dipeptidase, converts angiotensin I to angiotensin II by splitting off the dipeptide histidyl-leucine at the C-terminal of the decapeptide. The pulmonary circulation is the main site of conversion, but converting-enzyme is also present in the plasma, in the splanchnic system, in the kidney and in several other tissues. Angiotensin II is the effector hormone of the system in man. Its most important actions are direct pressor effects on the arteriolar smooth muscle, stimulation of the aldosterone secretion by the adrenal gland, and effects on the central and peripheral nervous system; these actions result in an increase of blood pressure and in salt and water retention.


Angiotensin Converting Enzyme Renin Angiotensin System Juxtaglomerular Apparatus Sodium Depletion Plasma Renin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. C. Khosla, R. R. Smeby, and F. M. Bumpus, Structure activity relationships in angiotensin.II analogs, in: “Angiotensin,” Springer, Berlin, p. 162 (1964).Google Scholar
  2. 2.
    D. T. Pals, F. D. Masucci, G. S. Denning, F. Dipos, and D. C. Fessier, Role of the pressor action of angiotensin II in experimental hypertension, Circ.Res. 29:673 (1971).PubMedCrossRefGoogle Scholar
  3. 3.
    L. Baer, J. Z. Parra-Carillo, and I. Radichevich, Angiotensin II blockade: Evidence for baroreceptor mediated renin release and the role of sodium balance, Kid. Int. 15:S60 (1979).Google Scholar
  4. 4.
    L. S. Marks, M. H. Maxwell, and J. J. Kaufman, Renin, sodium, and vasodepressor response to saralasin in renovascular and essential hypertension, Ann.Int.Med. 87:176 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    R. Fagard, A. Amery, P. Lijnen, and T. Reybrouck, Effects of angiotensin II antagonist l-sar-8-ala-angiotensin II in hypertension in man, Eur.J.C1in.Invest. 7:473 (1977).CrossRefGoogle Scholar
  6. 6.
    C. Thananopavarn, M. S. Golub, P. Eggena, J. D. Barrett, and M. P. Sambhi, Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension, Circulation 61:920 (1980)PubMedCrossRefGoogle Scholar
  7. 7.
    J. C. Romero, D. R. Holmes, and C. G. Strong, The effect of high sodium intake and angiotensin antagonist in rabbits with severe and moderate hypertension induced by constriction of one renal artery, Circ.Res. 40(Suppl.1): 17 (1977).CrossRefGoogle Scholar
  8. 8.
    D. B. Case, J. M. Wallace, H. J. Keim, J. E. Sealy, and J. H. Laragh, Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients, Am.J.Med. 60:825 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    H. Gavras, A. B. Ribeiro, I. Gavras, and H. R. Brunner, Reciprocal relation between renin dependency and sodium dependency in essential hypertension, New Engl.J.Med. 295: 1278 (1976).PubMedCrossRefGoogle Scholar
  10. 10.
    R. Fagard, A. Amery, P. Lijnen, T. Reybrouck, J. V. Joossens, L. Billiet, E. Moerman, and A. De Schaepdryver, Effects of l-sar-8-ala-angiotensin II on systemic and pulmonary haemodynamics in hypertensive patients, Clin.Exp.Physiol. Pharmacol. 5:457 (1978).CrossRefGoogle Scholar
  11. 11.
    H. R. Brunner, H. Gavras, J. H. Laragh, and R. Keenan, Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade, Circ.Res. 34(Suppl.1):35 (1974).Google Scholar
  12. 12.
    D. H. P. Streeten, G. H. Anderson, and T. G. Dalakos, Angiotensin blockade: its clinical significance, Am.J.Med. 60: 817 (1976).PubMedCrossRefGoogle Scholar
  13. 13.
    M. A. Ondetti, B. Rubin, and D. W. Cushman, Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents, Science 196:441 (1977).PubMedCrossRefGoogle Scholar
  14. 14.
    R. K. Ferguson, G. A. Turini, H. R. Brunner, and H. Gavras, A specific orally active inhibitor of angiotensin-converting enzyme in man, Lancet 1:775 (1977).PubMedCrossRefGoogle Scholar
  15. 15.
    R. Fagard, A. K. Amery, P. J. Lijnen, and T. M. Reybrouck, Comparative study of an angiotensin II analog and a converting enzyme inhibitor, Kid.Int. 17:647 (1980).CrossRefGoogle Scholar
  16. 16.
    O. A. Carretero, A. G. Scicli, and R. Maitra, Role of kinins in the pharmacological effects of converting enzyme inhibitors, in: “Angiotensin Converting Enzyme Inhibitors,” Urban & Schwarzenberg, Baltimore-Munich, p.105 (1981).Google Scholar
  17. 17.
    B. Rubin, M. J. Antonaccio, and Z. P. Horovitz, The antihypertensive effects of Captopril in hypertensive animal models, in: “Angiotensin Converting Enzyme Inhibitors,” Urban & Schwarzenberg, Baltimore-Munich, p. 27 (1981).Google Scholar
  18. 18.
    R. C. Heel, R. N. Brogden, T. M. Speight, and G. S. Avery, Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy, Drugs 20:409 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    R. Fagard, A. Amery, T. Reybrouck, P. Lijnen, and L. Billiet, Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converting enzyme inhibition with Captopril in hypertensive patients, Am.J.Cardiol. 46:295 (1980).PubMedCrossRefGoogle Scholar
  20. 20.
    R. Fagard, A. Amery, P. Lijnen, and J. Staessen, First dose effects of the oral angiotensin converting enzyme inhibitor Captopril, Arch.Int.Pharmacodyn.Ther. (Suppl.):179 (1980).Google Scholar
  21. 21.
    P. Lijnen, R. Fagard, J. Staessen, L. J. Verschueren, and A. Amery, Dose response in Captopril therapy of hypertension, Clin.Pharmacol.Ther. 28:310 (1980).PubMedCrossRefGoogle Scholar
  22. 22.
    R. Fagard, C. Bulpitt, P. Lijnen, and A. Amery, Response of the systemic and pulmonary circulation to converting enzyme inhibition at rest and during exercise in hypertensive patients, Circulation 65:33 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • R. Fagard
    • 1
  • P. Lijnen
    • 1
  • J. Staessen
    • 1
  • A. Amery
    • 1
  1. 1.Hypertension and Cardiovascular Rehabilitation Unit Dept. of PathophysiologyFaculty of Medicine University of LeuvenLeuvenBelgium

Personalised recommendations